AK

Akili IncNASDAQ AKLI Stock Report

Last reporting period 31 Dec, 2023

Updated —

Last price

Market cap $B

0.034

Micro

Exchange

XNAS - Nasdaq

AKLI Stock Analysis

AK

Uncovered

Akili Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.034

Dividend yield

Shares outstanding

78.101 B

Akili, Inc. (Akili), formerly Social Capital Suvretta Holdings Corp. I, is a digital medicine company engaged in the development of cognitive treatments through technologies. The Company develops digital therapeutics that combine science and technology to address cognitive impairments in patients. The Company’s software-based medicine is designed to directly target brain function and is delivered through engaging consumer entertainment. Akili’s platform is powered by proprietary therapeutic engines designed to target cognitive impairment at its source in the brain. The Company’s products include EndeavorRx, Selective Stimulus Management Engine (SSME), Body Brain Trainer (BBT) and Spatial Navigation (SNAV) Engine. EndeavorRx product is measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Akili’s products are delivered through captivating action video game experiences.

View Section: Eyestock Rating